Sports doping: Emerging designer and therapeutic β2-agonists

Clinica Chimica Acta

Volumn 425, Issue , 2013, Pages 242-258

  Fragkaki, A G ^a   Georgakopoulos, C ^b   Sterk, S ^c   Nielen, M W F ^c  

^a Olympic Athletic Center of Athens   (Greece)

^b Anti Doping Laboratory of Qatar ^*  (Qatar)

^c WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Beta agonists; Designer drugs; Detection methods; Doping control; Veterinary drugs

Indexed keywords

ADAMANTYL DERIVATIVE; BAMBUTEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BITOLTEROL; BROMCHLORBUTEROL; BROMOBUTEROL; CARBUTEROL; CIMATEROL; CIMBUTEROL; CLENBUTEROL; CLENCYCLOHEXEROL; CLENHEXYL; CLENPENTEROL; CLENPROPEROL; CLORPRENALINE; DICHLORISOPRENALINE; FENOTEROL; FORMOTEROL; GROWTH PROMOTOR; HEXOPRENALINE; INDOLE DERIVATIVE; ISOETARINE; ISOPRENALINE; ISOXSUPRINE; MABUTEROL; MAPENTEROL; ORCIPRENALINE; PHENYL UREA DERIVATIVE; PROCATEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL FOOD; BIOSENSOR; CATTLE; DOPING; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; THIN LAYER CHROMATOGRAPHY;

AAF; ADVERSE ANALYTICAL FINDING; BETA-AGONISTS; CAS; CATECHOL-O-METHYLTRANSFERASE; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; COMT; COPD; COURT OF ARBITRATION FOR SPORT; DESIGNER DRUGS; DETECTION METHODS; DOPING CONTROL; ELISA; ENZYME-LINKED IMMUNOSORBENT ASSAY; EU; EUROPEAN UNION; FDA; FOOD AND DRUG ADMINISTRATION; HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY; HIGH RESOLUTION MASS SPECTROMETRY; HP-TLC; HRMS; IAC; ICS; IMMUNOAFFINITY CHROMATOGRAPHY; INHALED CORTICOSTEROID; LABA; LAMA; LC-MS; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; LOD; LONG-ACTING ANTI-MUSCARINIC AGENT; LONG-ACTING Β(2)-AGONIST; MINIMUM REQUIRED PERFORMANCE LIMIT; MIP; MOLECULAR IMPRINTED POLYMER; MONOAMINE OXIDASE; MRPL; PCI; POSITIVE CHEMICAL IONIZATION; RADIOIMMUNOASSAY; RIA; SABA; SHORT-ACTING Β(2)-AGONIST; SOLID PHASE EXTRACTION; SPE; SPR; SURFACE PLASMON RESONANCE; THIN LAYER CHROMATOGRAPHY; TIME-OF-FLIGHT; TLC; TOF; ULTRA PRESSURE (OR PERFORMANCE) LIQUID CHROMATOGRAPHY; ULTRAVIOLET; UPLC; UV; VETERINARY DRUGS; WADA; WORLD ANTI-DOPING AGENCY; ΜΑΟ;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ASTHMA; CATTLE; DESIGNER DRUGS; DIETARY SUPPLEMENTS; DOPING IN SPORTS; ETHANOLAMINES; GROWTH SUBSTANCES; HUMANS; INDOLES; QUINOLONES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 84884327600     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.07.031     Document Type: Review

References (139)

1. Tashkin D.P., Fabbri L.M. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res 2010, 11:149-163.
2. Chung K.F., Caramori G., Adcock I.M. Inhaled corticosteroids as combination therapy with β-adrenergic agonists in airways disease: present and future. Eur J Clin Pharmacol 2010, 65:853-871.
3. Mapel D.W., Hurley J.S., Dalal A.A., Blanchette C.M. The role of combination inhaled corticosteroid/long-acting β-agonist therapy in COPD management. Prim Care Respir J 2010, 19:93-103.
4. Mak G., Hanania N.A. New bronchodilators. Curr Opin Pharmacol 2012, 12:238-245.
5. Bjerg A., Lundböck B., Lötvall J. The future of combining inhaled drugs for COPD. Curr Opin Pharmacol 2012, 12:252-255.
6. DeBellis R.J. Mechanism of action of long-acting bronchodilators. Clin Pulm Med 2005, 12:S10-S12.
7. Sears M.R., Ottosson A., Radner F., Suissa S. Long-acting β-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J 2009, 33:21-32.
8. 2-adrenoceptor agonists in asthma management. Respir Med 2005, 99:152-170.
9. 2-adrenergic receptor function, response and regulation. J Allergy Clin Immunol 2006, 117:18-24.
10. Johnson M. The β-adrenoceptor. Am J Respir Crit Care Med 1998, 158:146-153.
11. Barisione G., Baroffio M., Crimi E., Brusasco V. Beta-adrenergic agonists. Pharmaceuticals 2010, 3:1016-1044.
12. 2-adrenoceptor agonists. Clin Rev Allergy Immunol 2006, 31:119-130.
13. Mazzoni L., Naef R., Chapman I.D., Morley J. Hyperresponsiveness of the airways following exposure of guinea-pigs to racemic mixtures and distomers of beta(2)-selective sympathomimetics. Pulm Pharmacol 1994, 7:367-376.
14. World Anti-Doping Agency The world anti-doping code, the 2013 prohibited list [accessed 21.02.2013]. http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/2013/WADA-Prohibited-List-2013-EN.pdf.
15. Weiler J.M., Ryan E.J. Asthma in United States Olympic athletes who participated in the 1998 Olympic Winter Games. J Allergy Clin Immunol 2000, 106:267-271.
16. [accessed 21.02.2013]. http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-IS-Laboratories/Technical_Documents/WADA-TD2013MRPL-Minimum-Required-Performance-Levels-v1-2012-EN.pdf.
17. [accessed 21.02.2013]. http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-IS-Laboratories/Technical_Documents/WADA-TD2013DL-Decision-Limits-for-the-Confirmatory-Quantification-Threshold-Substances-EN.pdf.
18. [accessed 15.2.2013]. http://www.wada-ama.org/Documents/Resources/Testing-Figures/WADA-2011-Laboratory-Testing-Figures.pdf.
19. Bueren A., Ma R., Schlumpf M., Lichtensteiger W. Salbutamol exhibits androgenic activity in vitro. Br J Sports Med 2007, 41:874-878.
20. Bonnet N., Benhamou C.L., Beaupied H., et al. Doping doses of salbutamol and exercise: deleterious effect on cancellous and cortical bones in adult rats. J Appl Physiol 2007, 102:1502-1509.
21. 2-agonists and exercise performance in humans. Sci Sports 2010, 25:281-290.
22. 2-adrenoceptor agonist salmeterol are dependent on route of administration. Am J Physiol 1994, 267:E475-E484.
23. [accessed 30.05.2013]. http://ww2.aanabolic.com/clenbuterol.html.
24. Beermann D.H. Beta-adrenergic receptor agonist modulation of skeletal muscle growth. J Anim Sci 2002, 80:E18-E23.
25. Kim Y.S., Sainz R.D., Summers R.J., Molenaar P. Cimaterol reduces beta-adrenergic receptor density in rat skeletal muscles. J Anim Sci 1992, 70:115-122.
26. 2-receptor agonist. Am J Physiol 1988, 254:E726-E732.
27. 2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses. Br J Pharmacol 2006, 147:587-595.
28. Yang Y.T., McElligott M.A. Multiple actions of beta-adrenergic agonists on skeletal muscle and adipose tissue. Biochem J 1989, 261:1-10.
29. Torgan C.E., Etgen J.G., Kang H.Y., Ivy L. Fiber type-specific effects of clenbuterol and exercise training on insulin-resistant muscle. J Appl Physiol 1995, 79:163-167.
30. Ingalls C.P., Barnes W.S., Smith S.B. Interaction between clenbuterol and run training: effects on exercise performance and MLC isoform content. J Appl Physiol 1996, 80:795-801.
31. Duncan N., Williams D., Lynch G. Deleterious effects of chronic clenbuterol treatment on endurance and sprint exercise performance in rats. Clin Sci 2000, 98:339-347.
32. 2-agonist treatments: bone mass, microarchitecture and strength analyses in female rats. Bone 2005, 37:622-633.
33. Mazzanti G., Daniele C., Boatto G., Manca G., Brambilla G., Loizzo A. New β-adrenergic agonists used illicitly as growth promoters in animal breeding; chemical and pharmacodynamic studies. Toxicology 2003, 187:91-99.
34. Estrada-Montoya M.C., González-Córdova A.F., Torrescano G., Camou J.P., Vallejo-Cordoba B. Screening and confirmatory determination of clenbuterol residues in bovine meat marketed in the northwest of Mexico. Cienc Tecnol Aliment 2008, 6:130-136. [Abstract].
35. Reig M., Toldrá F. Veterinary drug residues in meat: concerns and rapid methods for detection. Meat Sci 2008, 78:60-67.
36. [assessed 21.02.2013]. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:1996L0022:20081218:EN:PDF.
37. [assessed 21.02.2013]. http://ec.europa.eu/food/food/chemicalsafety/residues/council_directive_96_23ec.pdf.
38. [assessed 21.02.2013]. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2002:221:0008:0036:EN:PDF.
39. Cartanà J., Segues T., Yebras M., Rothwell N.J., Stock M.J. Anabolic effects of clenbuterol after long-term treatment and withdrawal in the rat. Metabolism 1994, 43:1086-1092.
40. Kim Y.S., Sainz R.D. β-Adrenergic agonists and hyperthrophy of skeletal muscles. Life Sci 1992, 50:397-407.
41. Cartanà J., Stock M.J. Effects of digoxin on the anabolic response to clenbuterol. Metabolism 1994, 43:959-964.
42. Hooijerink H., Schilt R., Haasnoot W. Determination of clenbuterol in urine of calves by high-performance liquid chromatography with in series ultraviolet and electrochemical detection. J Pharm Biomed Anal 1991, 9:485-492.
43. Delahaut P., Dubois M., Pri-Bar I. Development of a specific radioimmunoassay for the detection of clenbuterol residues in treated cattle. Food Addit Contam 1991, 8:43-53.
44. Montesissa C., Anfossi P., Biancotto G., Angeletti R. In vitro metabolism of clenbuterol and bromobuterol by pig liver microsomes. Xenobiotica 1998, 28:1049-1060.
45. Zalco D., Perdu-Durand E., Debrauwer L., Bec-Ferte M., Tulliez J. Comparative metabolism of clenbuterol by rat and bovine liver microsomes and slices. Drug Metab Dispos 1998, 26:28-35.
46. Pietraforte D., Brambilla G., Camerini S., et al. Formation of an adduct by clenbuterol, a β-adrenoceptor agonist drug, and serum albumin in human saliva at the acidic pH of the stomach: evidence for an aryl radical-based process. Free Radic Biol Med 2008, 45:124-135.
47. Guddat S., Fuβhöller G., Geyer H., et al. Clenbuterol-regional food contamination as possible source for positive findings in doping control? February 13-18, 2011, Presented at: 29th Cologne Workshop on Dope Analysis, Cologne, Germany.
48. [accessed 17.02.2013]. http://sportsillustrated.cnn.com/2011/more/wires/02/15/2080.ap.doping.clenbuterol.study.0711/index.html.
49. Hemmersbach P., Tomten S., Nilsson S., Ofterdo H., Havrevoll O., Oen B. Illegal use of anabolic agents in animal fattening-consequences for doping analysis. Recent advances in doping analysis 1995, 195-201. Sport und Buch Strauβ, Köln, Germany.
50. [accessed 27.04.2013]. http://www.nada-bonn.de/fileadmin/user_upload/nada/News-Bilder/110405_Clenbuterol_Warning_for_Mexico1.pdf.
51. Thevis M., Thomas A., Beuck S., Butch A., Dvorak J., Schänzer W. Does the analysis of the enantiomeric composition of clenbuterol in human urine enable the differentiation of illicit clenbuterol administration from food contamination in sports drug testing?. Rapid Commun Mass Spectrom 2013, 27:507-512.
52. [assessed 21.02.2013]. http://www.wada-ama.org/Documents/Science_Medicine/Funded_Research_Projects/2011/Review%20S%20%20Sterk%2011A18SS.pdf.
53. Maistro S., Chiesa E., Angeletti R., Brambilla G. Beta-blockers to prevent clenbuterol poisoning. Lancet 1990, 346:180.
54. Brambilla G., Loizzo A., Fontana L., Brambilla G. Food poisoning following consumption of clenbuterol-treated veal in Italy. JAMA 1997, 278:635.
55. Satpathy B.B., Mukherjee D., Ray A.K. Effects of dietary inclusion of the beta-adrenergic agonist, salbutamol, on growth performance and whole-body composition of rofu Labeo rohita (Hamilton) fingerlings fed diets containing two protein levels. Aquac Res 2001, 32:739-747.
56. Mustin W.T., Lovell R.T. Feeding the repartitioning agent, ractopamine, to channel cat fish (Letalurus punctatus) increases weight gain and reduces fat disposition. Aquaculture 1993, 109:145-152.
57. 2-adrenergic agonists on raibow trout muscle proteases and proteins. Comp Biochem Physiol 2006, 144:145-154.
58. 2-receptor agonist: metabolism and pharmacology. J Allergy Clin Immunol 1981, 68:91-97.
59. Şenyuva H.Z., Gilbert J. Immunoaffinity column clean-up techniques in food analysis: a review. J Chromatogr B 2010, 878:115-132.
60. Hage D.S., Anguizola J.A., Bi C., et al. Pharmaceutical and biomedical applications of affinity chromatography: recent trends and developments. J Pharm Biomed Anal 2012, 69:93-105.
61. Caro E., Marce R.M., Cormack P.A.G., Sherrington D.C., Borrull F. Novel enrofloxacin imprinted polymer applied to the solid-phase extraction of fluorinated quinolones from urine and tissue samples. Anal Chim Acta 2006, 562:145-151.
62. Tamayo F.G., Turiel E., Martín-Esteban A. Molecularly imprinted polymers for solid-phase extraction and solid-phase microextraction: recent developments and future trends. J Chromatogr A 2007, 1152:32-40.
63. Ramstrom O., Skudar K., Haines J., Patel P., Bruggemann O. Food analyses using molecularly imprinted polymers. J Agric Food Chem 2001, 49:2105-2114.
64. Samarajeewa U., Wei C.I., Huang T.S., Marshall M.R. Application of immunoassay in the food industry. Crit Rev Food Sci Nutr 1991, 29:403-434.
65. Boyd S., Heskamp H.H., Bovee T.F.H., Nielen M.W.F., Elliott C.T. Development, validation and implementation of a receptor based bioassay capable of detecting a broad range of beta-agonist drugs in animal feedstuff. Anal Chim Acta 2009, 637:24-32.
66. McGrath T.F., Elliott C.T., Fodey T.L. Biosensors for the analysis of microbiological and chemical contaminants in food. Anal Bioanal Chem 2012, 403:75-92.
67. Gillis E.H., Gosling J.P., Sreenan J.M., Kane M. Development and validation of a biosensor-based immunoassay for progesterone in bovine milk. J Immunol Methods 2002, 267:131-138.
68. Johansson M.A., Hellenas K.E. Sensor chip preparation and assay construction for immunobiosensor determination of beta-agonists and hormones. Analyst 2001, 126:1721-1727.
69. 2-agonists by hyphenated chromatographic and mass spectrometric techniques. J Chromatogr B 1996, 687:27-42.
70. 2-agonists by gas chromatographic-mass spectrometric analysis. J Mass Spectrom 2000, 35:1285-1294.
71. 2-agonists and 5 β-blockers in animal muscle by high performance liquid chromatography-linear ion trap mass spectrometry. Sci China B 2010, 53:832.
72. Peters R.J.B., Oosterink J.E., Stolker A.A.M., Georgakopoulos C., Nielen M.W.F. Generic sample preparation combined with high-resolution liquid chromatography-time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories. Anal Bioanal Chem 2010, 396:2583-2598.
73. 2-agonists in human urine by fast-gas chromatography/mass spectrometry: method validation and clinical application. Biomed Chromatogr 2010, 24:358-366.
74. Van Eenoo P., Van Gansbeke W., De Brabanter N., Deventer K., Delbeke F.T. A fast, comprehensive screening method for doping agents in urine by gas chromatography-triple quadrupole mass spectrometry. J Chromatogr A 2011, 1218:3306-3316.
75. 2-adrenergic receptor binding assay in transfected HEK-293 cells. Anal Chim Acta 2005, 529:53-56.
76. 2-agonist drugs of new generation from bovine urine and hair by α1-acid glycoprotein affinity chromatography and determination by gas chromatography-mass spectrometry. Anal Chim Acta 2007, 587:67-74.
77. 2-adrenoceptor. Bioorg Med Chem Lett 2010, 20:5623-5629.
78. 2. J Mol Model 2009, 15:1203-1211.
79. Anderson G.P., Lindėn A., Rabe K.F. Why are long-acting beta-adrenoceptor agonists long-acting?. Eur Respir J 1994, 7:569-578.
80. 2-adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J Med Chem 2010, 53:4522-4530.
81. 2 adrenergic receptor agonists incorporating arylsulfonamide groups. J Med Chem 2009, 52:2280-2288.
82. 2-adrenoreceptor agonists. Bioorg Med Chem Lett 2007, 17:4012-4015.
83. 2-adrenoceptor agonists for the treatment of asthma and COPD. Bioorg Med Chem Lett 2007, 17:6188-6191.
84. 2-adrenoreceptor agonists. Bioorg Med Chem Lett 2008, 18:1280-1283.
85. 2-adrenoreceptor agonists. Bioorg Med Chem Lett 2011, 21:1545-1548.
86. 2-adrenoceptor agonists for the treatment of chronic obstructive pulmonary disease: the pre-clinical rationale. Respir Med 2002, 97:S3-S7.
87. 2-adrenoceptor agonist, Viozan™: chronic obstructive pulmonary disease and drug development implications. Respir Med 2003, 97:S71-S74.
88. 2-adrenoceptor agonists. Bioorg Med Chem Lett 2011, 21:4612-4616.
89. 2-agonists. Bioorg Med Chem Lett 2011, 21:4027-4031.
90. 2-adrenoceptor agonists. Bioorg Med Chem Lett 2012, 22:689-695.
91. Cazzola M., Matera M.G. Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol 2008, 155:291-299.
92. 2-agonists in the management of COPD: biological and pharmacological aspects. Drug Discov Today 2012, 17:496-504.
93. 2-Adrenoceptor agonists: current and future direction. Br J Pharmacol 2011, 163:4-17.
94. 2-adrenoceptor agonist. J Med Chem 2010, 53:3675-3684.
95. Chuchalin A.G., Tsoi A.N., Richter K., et al. Safety and tolerability of indacaterol in asthma: a randomized, placebo-controlled 28-day study. Respir Med 2007, 101:2065-2071.
96. Matera M.G., Page C.P., Cazzola M. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol Sci 2011, 32:495-506.
97. 2-adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 2006, 317:762-770.
98. Moen D.M. Indacaterol: in chronic obstructive pulmonary disease. Drugs 2010, 70:2269-2280.
99. 2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010, 65:473-479.
100. 2-adrenoceptor agonist indacaterol. Bioorg Med Chem Lett 2012, 22:6280-6285.
101. 2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther 2012, 26:256-264.
102. Martinez F.J., Boscia J., Feldman G., et al. Fluticasone furoate/vilanterol (100/25; 200/25μg) improves lung function in COPD: a randomised trial. Respir Med 2013, 107:550-559.
103. 2-adrenoceptor agonist, in bronchodilating effect in guinea pigs. Biol Pharm Bull 2008, 31:866-872.
104. 2-selectivity of SPFF, a newly developed bronchodilating agent, in guinea pigs and rabbits. Biol Pharm Bull 2003, 26:323-328.
105. 2-adrenoceptor agonist trantinterol and its metabolites in beagle dog urine. Biomed Chromatogr 2010, 24:274-280.
106. 2-selectivity of TA-2005, a newly developed bronchodilating agent, in isolated guinea pig tissues. Jpn J Pharmacol 1991, 57:175-185.
107. 2-agonist carmoterol given as a 2mg qd dose; 8days comparison with formoterol and placebo in patients with persistent asthma. Eur Respir J 2006, 28:665s-671s.
108. Acerbi D., Brambilla G., Kottakis I. Advances in asthma and COPD management: delivering CFC-free inhaled therapy using Modulite® technology. Pulm Pharmacol Ther 2007, 20:290-303.
109. 2-adrenoceptor agonist, TA 2005. Eur J Pharmacol 1992, 227:403-409.
110. 2-agonist olodaterol in COPD. Pulm Pharmacol Ther 2011, 24:666-672.
111. 2-adrenoceptor agonist with a 24h bronchodilatory efficacy. Bioorg Med Chem Lett 2010, 20:1410-1414.
112. 2-agonist, in patients with mild asthma. J Allergy Clin Immunol 2009, 124:1217-1721.
113. Caracosa P., Kollak I., Kiechle T., et al. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol. J Pharmacol Exp Ther 2011, 337:600-609.
114. 2-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup. J Med Chem 2010, 53:6640-6652.
115. 2-adrenoceptor agonist, PF-00610355 in asthmatic patients. Eur Respir J 2009, 34:778s-780s. [abstract].
116. 2-adrenoceptor agonist. Eur Respir J 2009, 34:777s-778s. [abstract].
117. 2-adrenoceptor agonists. Drugs 2007, 67:503-515.
118. Aparici M., Gomez-Angelats M., Vilella D., et al. The in vitro pharmacological profile of LAS100977 - a potent, selective and long-acting beta-2 receptor agonist. Am J Respir Crit Care Med 2010, 181:A5675-A5678.
119. 2-agonist, show high activity and long duration in healthy subjects. Am J Respir Crit Care Med 2010, 181:A5663-A5668. [abstract].
120. 2-agonist in patients with persistent asthma. Am J Respir Crit Care Med 2010, 181:A5414-A5419.
121. Cazzola M., Segreti A., Matera M.G. Novel bronchodilators in asthma. Curr Opin Pulm Med 2010, 16:6-12.
122. 2-adrenoceptor agonist (uLABA), with formoterol in patients with asthma. J Allergy Clin Immunol 2012, 129:AB241. [abstract].
123. 2-agonist, in patients with COPD. Eur Respir J 2011, 38:148s. [abstract].
124. 2-adrenoreceptor agonist (uLABA) bronchodilator. J Allergy Clin Immunol 2012, 129:AB76. [abstract].
125. 2-adrenoceptor agonist with rapid onset and long duration of action. Pulm Pharmacol Ther 2012, 25:293-302.
126. Berendsen B.J.A., Stokler A.A.M., Nielen M.W.F. Selectivity in the sample preparation for the analysis of drug residues in products of animal origin using LC-MS. Trends Anal Chem 2013, 43:229-239.
127. Stolker A.A.M., Brinkman U.A.T. Analytical strategies for residue analysis of veterinary drugs and growth-promoting agents in food-producing animals-a review. J Chromatogr A 2005, 1067:15-53.
128. Van der Heeft E., Bolck Y.J.C., Beurer B., Nijrolder A.J.W.M., Stolker A.A.M., Nielen M.W.F. Full-scan accurate mass selectivity of ultra-performance liquid chromatography combined with time-of-flight and orbitrap mass spectrometry in hormone and veterinary drug residue analysis. J Am Soc Mass Spectrom 2009, 20:451-463.
129. Kaufmann A., Widmer M., Maden K. Post-interface signal suppression, a phenomenon observed in a single-stage Orbitrap mass spectrometer coupled to an electrospray interfaced liquid chromatograph. Rapid Commun Mass Spectrom 2010, 24:2162-2170.
130. Trufelli H., Palma P., Famiglini G., Cappiello A. An overview of matrix effects in liquid chromatography-mass spectrometry. Mass Spectrom Rev 2011, 30:491-509.
131. Berendsen B.J.A., Wegh R.S., Essers M.L., Stolker A.A.M., Weigel S. Quantitative trace analysis of a broad range of antiviral drugs in poultry muscle using column-switch liquid chromatography coupled to tandem mass spectrometry. Anal Bioanal Chem 2012, 402:1611-1623.
132. Regal P., Diaz-Bao M., Barreiro A.C., Fente C. Application of molecularly imprinted polymers in food analysis: clean-up and chromatographic improvements. Cent Eur J Chem 2012, 10:766-784.
133. Mei H., Hsieh Y., Nardo C., et al. Investigation of matrix effects in bioanalytical high-performance liquid chromatography/tandem mass spectrometric assays: application to drug discovery. Rapid Commun Mass Spectrom 2003, 17:97-103.
134. Mallet C.R., Lu Z., Mazzeo J.R. A study of ion suppression effects in electrospray ionization from mobile phase additives and solid-phase extracts. Rapid Commun Mass Spectrom 2004, 18:49-58.
135. Le Bizec B., Pinel G., Antignac J.P. Options for veterinary drug analysis using mass spectrometry. J Chromatogr A 2009, 1216:8016-8034.
136. Meinert C., Meierhenrich U.J. A new dimension in separation science: comprehensive two-dimensional gas chromatography. Angew Chem Int Ed Engl 2012, 51:10460-10470.
137. Holčapek M., Jirásko R., Lísa M. Recent developments in liquid chromatography-mass spectrometry and related techniques. J Chromatogr A 2012, 1259:3-15.
138. Silva A.I., Pereira H.M.G., Casilli A. Analytical challenges in doping control: comprehensive two-dimensional gas chromatography with time of flight mass spectrometry, a promising option. J Chromatogr A 2009, 1216:2913-2922.
139. Nielen M.W.F., Elliott C.T., Boyd S.A., et al. Identification of an unknown β-agonist in feed by liquid chromatography/bioassay/quadrupole time-of-flight tandem mass spectrometry with accurate mass measurement. Rapid Commun Mass Spectrom 2003, 17:1633-1641.